Advertisement
Advertisement
AMRN
Amarin Corp Plc
14.36
USDSponsored
+0.10
+0.70%
Aug 07, 15:59 UTC -4
Closed
After-Market
14.49
+0.13
+0.91%
AMRN Earnings Reports
Positive Surprise Ratio
AMRN beat 28 of 43 last estimates.
65%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$42.25M
/$0.00
Implied change from Q2 26 (Revenue/ EPS)
+0.09%
/-100.00%
Implied change from Q3 25 (Revenue/ EPS)
-14.94%
/-100.00%
Amarin Corp Plc earnings per share and revenue
On Jul 29, 2026, AMRN reported earnings of 0.04 USD per share (EPS) for Q2 26, beating the estimate of -0.01 USD, resulting in a 492.16% surprise. Revenue reached 42.21 million, compared to an expected 45.44 million, with a -7.11% difference. The market reacted with a +1.51% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 42.25 million USD, implying an decrease of -100.00% EPS, and increase of 0.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Amarin Corp Plc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Amarin Corp Plc reported EPS of $0.04, beating estimates by 492.16%, and revenue of $42.21M, -7.11% below expectations.
How did the market react to Amarin Corp Plc's Q2 2026 earnings?
The stock price moved up 1.51%, changed from $13.95 before the earnings release to $14.16 the day after.
When is Amarin Corp Plc expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Amarin Corp Plc's next earnings report?
Based on 3
analysts, Amarin Corp Plc is expected to report EPS of -- and revenue of $42.25M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement